A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Efatutazone (Primary) ; Paclitaxel
- Indications Thyroid cancer
- Focus Therapeutic Use
- 30 Jan 2018 Status changed from suspended to recruiting.
- 12 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jul 2019.
- 20 Jun 2017 Status changed from recruiting to suspended in the Scheduled Interim Monitoring.